-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$67.3372.51% Upside
SpringWorks Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover SpringWorks Therapeutics, Inc.?
SpringWorks Therapeutics, Inc. has been rated by research analysts at H.C. Wainwright, Wedbush, Goldman Sachs in the past 90 days.